Product news

Share this article:
The FDA has broadened the US indication for Novartis' once-yearly Reclast (zoledronic acid) injection to include the prevention of new clinical fractures in patients who have recently had a low-trauma hip fracture.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Panel votes against painkiller

Panel chair Randall Flick said QRxPharma "had not provided sufficient evidence to support a claim that Moxduo is safer than morphine or oxycodone."

Amgen sales rose by 5% in Q1

But demand for Enbrel and Aranesp slipped.

FDA reviews new painkiller

The candidate would be the first to put oxycodone and morphine in one capsule.